AzTrials
AzTrials

WoundPROWOUNDNCT03210779

Effect of Probiotics on Oral Wound Healing - Pilot Study

A study testing L. reuteri DSM 17938/ATCC PTA in people with Wound, run by University of Copenhagen.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This research will study the healing of standardized wounds created in the oral mucosa of volunteer participants during daily intake of tablets and topical application of oil containing the probiotic bacterium Lactobacillus reuteri. Read more about this study

Who is it for?
Ages 18 to 50 yearsHealthy volunteers can take part
Conditions the study is for
Wound
What is being tested?
L. reuteri DSM 17938/ATCC PTA
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
10 participants
Where
No sites listed yet
Study dates
5 Dec 2016to 30 Jun 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Healthy individuals (no chronic compromising illnesses)
  • Healthy oral conditions
  • Good level of oral hygiene

Who cannot join

  • Adults over 50 years old
  • Previous allergic reaction to local anesthetics
  • Compromised oral mucosa
  • Systemic diseases
  • Obesity
  • Alcoholism
Show all 14Show fewer
  • Smoking habit
  • Pregnancy
  • Antibiotic therapy within the last two months
  • Active infection that needs treatment with antibiotics
  • Systemic medications (glucocorticoid steroids, non-steroidal anti-inflammatory drugs -NSAIDS, chemotherapy, anticoagulant therapy) Contraceptives allowed.
  • Thrombocytopenia or any of various inherited coagulopathies.
  • Patients undergoing radiotherapy
  • Inability to provide informed consent by means of physical or mental handicap

About this study

Official title: Effect of Probiotic Tablets and Topical Probiotic Oil (Lactobacillus. Reuteri) on Oral Wound Healing (Pilot Study)

This research will study the healing of standardized wounds created in the oral mucosa of volunteer participants during daily intake of tablets and topical application of oil containing the probiotic bacterium Lactobacillus reuteri. Our null hypothesis is that the consumption and topical application of probiotic supplements containing L. reuteri does not improve clinical healing of oral wounds in healthy participants when compared to controls.

Read the detailed description

Intervention: after informed consent and baseline collection of clinical data (age,sex), the participants will be randomly assigned to one of the order of the treatments. As a run-in period, they will be given a supply of probiotic or placebo tablets enough for seven days. The participants are instructed to take two tablets daily (one in the morning and one in the evening, days 0-7) and are asked to refrain from any other foods or supplements containing probiotics. On day eight, the participant will attend to the clinics and a punch biopsy will be performed. Depending on the allocation group, probiotic or placebo oil will be supplied. The participant will be instructed to apply the oil locally on the wound with a plastic microbrush for 9 days every evening, and strongly reinforced to continue with the assigned tablets twice daily. The participant will attend the clinics on days two, five and eight post-wounding for follow-up photographies of wound healing. The first intervention period terminates with a wash-out period of four weeks, and then the second run-in an intervention period start following the same procedures.

The probiotic tablets and the probiotic oil (at the recommended dose) contain 2x10^8 CFU of Lactobacillus reuteri. Both the placebo tablets and oil are identical in size and composition but without the addition of the probiotic strains. The tablets and oil are packed in identical pots/bottles with color coding. The code will be kept from the investigators until the analysis are finished. Both the tablets and oil are provided by BIOGAIA AB.

Clinical procedures and sampling

All clinical procedures and sample collections will be conducted by a qualified and authorized dentist from the Institute of Odontology, Section for Cariology, Endodontics, Pediatric Dentistry and Clinical Genetics, Faculty of Health and Medical Sciences, University of Copenhagen. Collected samples (saliva, wound exudate and bacterial smear) will be stored in a freezer at -80 °C until all samples from all patients are gathered -for a maximum of six months. Running of all collected samples at the same time allows laboratory analyses to be carried out efficiently and avoids errors.

Punch biopsy: on day eight, a standardized circular wound of 3.5 mm diameter and approximately 1.5 mm deep will be created in the mucosa of the hard palate with aid of a biopsy punch. The biopsy is performed under aseptic conditions and local anesthesia using lidocaine 2% combined with epinephrine for local hemostasis. A scalpel is used to remove the surface epithelium and underlying superficial connective tissue, which will be discarded according to biosafety regulations from the Institute of Dentistry, University of Copenhagen. After wounding, the wound site will be photographed (blind-coded) with an intraoral camera, placing a standard-sized 6 mm diameter template around the wound as reference. The participant will attend to the dental clinics on days two, five and eight post-wounding to have a photograph of the wound taken by Ph.D student Gina Castiblanco. The wound-size on photographs will be measured by two raters and will be expressed as the ratio of the wound surface area relative to the standard label size with aid of software (Canvas 7, ACD Systems of America). The endpoint will be the percentage of initial wound size, measured at days two, five and eight post-wounding.

Saliva sampling: six samples of unstimulated whole saliva (UWS) fro m each subject will be collected (one at baseline, one right after the run-in period and one at the end of the intervention period). For USW collection, the participant will be sitting in a comfortable position with the head slightly bent. The participant is asked to keep the eyes open and make as few moves as possible, including swallowing. Then, he/she is asked to rinse the mouth in water and spit it out again. Thereafter, he/she is instructed to let saliva flow out of the mouth down a designated plastic cup for ten minutes. Aliquots of saliva (1.5 ml) will immediately be placed on ice and stored in a freezer at -80 °C until further analysis.

Collection of wound exudate: eight samples of wound exudate will be collected in total. The wound site will be dried with cotton pellets and periopaper strips (ProFlow, Amityville, NY, USA) will be gently pressed on the wound for 20 s. In case of blood contamination, the strip is discharged and the sampling is repeated after five min. The volume of exudate is recorded using a Peritron 8000 (Proflow) and expressed in µL. One strip holds approximately 0.1-0.4 µL of exudate. The strips are then transferred to plastic tubes and stored at -80 until further analysis.

Bacterial smear collection: four bacterial smears will be sampled. A sterile swab will be passed through the wound site, placed in a plastic tube and stored freezed at -80 °C until further analysis. The smears will be subjected to conventional microbial cultivation to detects the presence/absence and counts of bacterial species commonly associated with delayed wound healing (β-hemolytic streptococci and S. aureus).

Perception of pain and discomfort: a one-page logbook will be handed to the participants at the beginning of each run-in period so they can register the intake of tablets and their own perception of pain and discomfort according to a VAS-scale. The participant is also encouraged to register factors that could possibly influence the outcome (physical activity and number of alcoholic drinks). The participant will be asked to bring the filled logbook in the end of the intervention period.

Perceived stress and general health: in the end of the intervention period, the participant will be asked to fill the validated General Heath Questionnaire GHQ-12 (10) and the validated Perceived Stress Scale (11). These factors (self-perception of stress and general health) are known to be possible cofounders of wound healing outcomes.

Compliance: at the beginning of each intervention period, the participants will be provided with tablets enough for 16 days and oil for topical use enough for nine days application. Compliance will be checked through the participant´s completion of a logbook in which the daily intake of tablets and oil application is registered. For the last appointment, the participants will be asked to bring the remaining tablets and oil for counting/estimating.

Data analysis: all data will be processed with the open source statistics software "R" and controlled for normal distribution. Multivariate and univariate analysis of variance (MANOVAs and ANOVAs) will be used to assess within-subject change over time. A p-value less than 0.05 will be considered statistically significant. The obtained results will be published in an internationally recognized journal. If the results cannot be published in a journal, they will be available at the website of the University of the Odontology Institute. We make emphasis in that positive, negative and inconclusive results will be published.

Data management: all collected data will be treated in compliance with the Act on Processing of Personal Data and "The Health Law". At inclusion the participants will be assigned a unique number and a separate protocol without personal identification number. This study will not be reported to "Datatilsynet" as it is a private scientific health project

Conditions
Wound
Being tested
L. reuteri DSM 17938/ATCC PTA, Placebo
Keywords
oral wound healing, probiotics
Medical subject headings
Wounds and Injuries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • L. reuteri DSM 17938/ATCC PTADietary supplement

    Ingestion of active lozenge twice daily for 16 days and topical application of active oil once daily for 8 days

  • PlaceboDietary supplement

    Ingestion of inactive lozenge twice daily for 16 days application of inactive oil once daily for 8 days

Study groups in NCT03210779
Study groupRoleWhat they receive
L.reuteriActive comparatorL. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA lozenges three times daily for 16 days + L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA probiotic oil, topically, once daily for 8 days.
Receives: Dietary Supplement: L. reuteri DSM 17938/ATCC PTA
PlaceboPlacebo comparatorPlacebo lozenges three times daily for 16 days and placebo oil once daily for 8 days
Receives: Dietary Supplement: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage (%) of initial wound size area, measured in digital photographs

    The reference value (100%) will be the area before intervention. The percentage is calculated with the second measure (photograph after the intervention)

    Measured: 8 days

Secondary outcomes (3)
  1. Levels of salivary oxytocin and salivary IL-10, in pg/ml

    As measured with standardized immuno-assays (ELISA kits)

    Measured: 8 days

  2. Levels of TNF-α and Interleukin 1β in the wound exudate

    As measured with standardized immuno-assays (ELISA kits)

    Measured: 8 days

  3. Numerical estimation of S. aureus and β-haemolitic streptococci (CFU/ml)

    As measured from bacterial cultures obtained from wound smears

    Measured: 8 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jul 2017
  2. Study start5 Dec 2016
  3. Primary completion30 Jun 2017
  4. Study completion30 Jun 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Crossover
Model description
Cross-over pilot trial
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03210779
Sponsor's protocol ID
2016-2430
Acronym
PROWOUND
Status last verified
May 2018
First submitted
3 Jul 2017
Last updated
22 May 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Erdman SE, Poutahidis T. Probiotic 'glow of health': it's more than skin deep. Benef Microbes. 2014 Jun 1;5(2):109-19. doi: 10.3920/BM2013.0042.

    PubMed 24675231
  • Twetman S, Pedersen AML, Yucel-Lindberg T. Probiotic supplements containing Lactobacillus reuteri does not affect the levels of matrix metalloproteinases and interferons in oral wound healing. BMC Res Notes. 2018 Oct 25;11(1):759. doi: 10.1186/s13104-018-3873-9.

    PubMed 30359300

Questions about this trial

What is this clinical trial studying?

A study testing L. reuteri DSM 17938/ATCC PTA in people with Wound, run by University of Copenhagen.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 May 2018. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage (%) of initial wound size area, measured in digital photographs (time frame: 8 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03210779, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in